NFKB1 and AL amyloidosis: While proteasome inhibitors, such as bortezomib, can provide significant clinical benefit in multiple myeloma and a few other indications, these agents inhibit NF-κB and many other essential cellular pathways that rely on the proteasome function [6,162,166], and are therefore by no means specific for the NF-κB pathway.